Full-Time
Business Development Associate
Confirmed live in the last 24 hours
Asimov
51-200 employees
Integrated platform for genetic design and engineering
Mid, Senior
Remote in UK
- At least 3 years’ experience in a business development or sales role, ideally within the B2B biopharmaceutical tools and/or services sector.
- A deep understanding of the biotherapeutics manufacturing landscape.
- Ability to rapidly build rapport and effectively communicate the benefits of partnering with Asimov.
- Proven track record of growing long-term relationships with clients.
- Knowledge of cell line development and upstream process development for biologics and/or viral vectors.
- A Master's degree in a biologics-based discipline is preferred. Alternatively, a Bachelor's degree in Life Sciences coupled with relevant experience will be considered.
- Proactively source and secure business opportunities with biopharma companies ranging from virtual organisations to big pharma in order to drive significant revenue growth.
- Play a central role in building and nurturing relationships with clients, focusing on customer centricity.
- Effectively convey the technical and commercial benefits of our offerings to potential clients.
- Work closely with the broader Commercial Team to develop deal structures that maximise value for all parties involved.
- Represent Asimov at industry conferences, network with potential partners, and grow awareness of our technologies and services.
Asimov offers a conducive environment for professionals passionate about genetic engineering, providing an integrated platform that includes engineered host cells, a genetic parts library, and advanced cloud-based design software. The company excels in the biotechnology field with its expertise in rationally-designed vectors, transposase-mediated integration, and scalable production of viral vectors, positioning it as a leader in biologics and gene therapies development. This focus on cutting-edge technology and substantial industry contributions makes it an ideal workplace for innovation-driven individuals.
Company Stage
Series B
Total Funding
$204.7M
Headquarters
Boston, Massachusetts
Founded
2017
6 month growth
↑ 0%1 year growth
↑ 23%2 year growth
↑ 86%
Simplify's Take
What believers are saying
- The launch of the LV Edge Producer System promises scalable, reproducible, and low-cost production of lentivirus, potentially unlocking larger therapeutic applications.
- The establishment of Asimov Labs with The Foundry team enhances Asimov's R&D capabilities, driving forward advanced genetic design and engineering.
- Asimov's innovative approach to synthetic biology and biocomputing could lead to significant breakthroughs in therapeutic development and manufacturing.
What critics are saying
- The complexity of integrating The Foundry's team and infrastructure into Asimov could pose operational challenges.
- The reliance on advanced genetic and computational tools may require substantial ongoing investment in R&D, impacting financial stability.
What makes Asimov unique
- Asimov's LV Edge System offers a unique fully stable cell line development service, eliminating GMP plasmid costs and reducing process complexity, unlike traditional multi-plasmid transfection methods.
- The integration of The Foundry's advanced genetic design capabilities from MIT and the Broad Institute positions Asimov at the forefront of genetic engineering innovation.
- Asimov's focus on combining cellular, genetic, and computational tools to enable next-generation therapeutics sets it apart from competitors who may specialize in only one of these areas.